{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:26:39Z","timestamp":1793175999364,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amyotrophic lateral sclerosis is a complex disorder most of which is \u2018sporadic\u2019 of unknown origin but approximately 10% is familial, arising from single mutations in any of more than 30 genes. Thus, there are more than 30 familial ALS subtypes, with different, often unknown, molecular pathologies leading to a complex constellation of clinical phenotypes. We have mouse models for many genetic forms of the disorder, but these do not, on their own, necessarily show us the key pathological pathways at work in human patients. To date, we have no models for the 90% of ALS that is \u2018sporadic\u2019. Potential therapies have been developed mainly using a limited set of mouse models, and through lack of alternatives, in the past these have been tested on patients regardless of aetiology. Cancer researchers have undertaken therapy development with similar challenges; they have responded by producing complex mouse models that have transformed understanding of pathological processes, and they have implemented patient stratification in multi-centre trials, leading to the effective translation of basic research findings to the clinic. ALS researchers have successfully adopted this combined approach, and now to increase our understanding of key disease pathologies, and our rate of progress for moving from mouse models to mechanism to ALS therapies we need more, innovative, complex mouse models to address specific questions.<\/jats:p>","DOI":"10.1186\/s13024-023-00619-2","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T18:02:30Z","timestamp":1683223350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Opinion: more mouse models and more translation needed for ALS"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-9936","authenticated-orcid":false,"given":"Elizabeth M.C.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Greensmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Fratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampietro","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Acevedo","family":"Arozena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"10360","key":"619_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363\u201380.","journal-title":"Lancet"},{"key":"619_CR2","doi-asserted-by":"publisher","first-page":"103795","DOI":"10.1016\/j.ebiom.2021.103795","volume":"75","author":"RC Vasta","year":"2022","unstructured":"Vasta RC, Traynor R, Chio BJ. Unraveling the complex interplay between genes, environment, and climate in ALS. eBioMedicine. 2022;75:103795.","journal-title":"eBioMedicine"},{"key":"619_CR3","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"619_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1468-1331.2009.02586.x","volume":"16","author":"A Alonso","year":"2009","unstructured":"Alonso A, et al. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745\u201351.","journal-title":"Eur J Neurol"},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"107674","DOI":"10.1016\/j.clineuro.2023.107674","volume":"227","author":"M Oliveira Santos","year":"2023","unstructured":"Oliveira Santos M, et al. Clinical characteristics in amyotrophic lateral sclerosis with Sub-Saharan Africa ancestry - A portuguese hospital-based cohort study. Clin Neurol Neurosurg. 2023;227:107674.","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"619_CR6","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00415-006-0195-y","volume":"253","author":"CA Johnston","year":"2006","unstructured":"Johnston CA, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253(12):1642\u20133.","journal-title":"J Neurol"},{"issue":"7\u20138","key":"619_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/21678421.2020.1779298","volume":"21","author":"C Bendotti","year":"2020","unstructured":"Bendotti C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7\u20138):485\u201395.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"12","key":"619_CR8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","volume":"53","author":"W van Rheenen","year":"2021","unstructured":"van Rheenen W, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636\u201348.","journal-title":"Nat Genet"},{"issue":"4","key":"619_CR9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","volume":"19","author":"BD Boros","year":"2022","unstructured":"Boros BD, et al. Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics. 2022;19(4):1145\u201358.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"619_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov VA, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104\u201316.","journal-title":"Nat Med"},{"issue":"4","key":"619_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s13311-022-01285-w","volume":"19","author":"KE Meijboom","year":"2022","unstructured":"Meijboom KE, Brown RH. Approaches to Gene Modulation Therapy for ALS. Neurotherapeutics. 2022;19(4):1159\u201379.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"619_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, et al. Phase 1\u20132 trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"619_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117\u201324.","journal-title":"Nat Med"},{"issue":"2","key":"619_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180\u201390.","journal-title":"Nat Neurosci"},{"issue":"7899","key":"619_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma XR, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124\u201330.","journal-title":"Nature"},{"issue":"7899","key":"619_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","volume":"603","author":"AL Brown","year":"2022","unstructured":"Brown AL, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131\u20137.","journal-title":"Nature"},{"issue":"6637","key":"619_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.abq5622","volume":"379","author":"MW Baughn","year":"2023","unstructured":"Baughn MW, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140\u20139.","journal-title":"Science"},{"issue":"3","key":"619_CR18","doi-asserted-by":"publisher","first-page":"fcab157","DOI":"10.1093\/braincomms\/fcab157","volume":"3","author":"L Rolfes","year":"2021","unstructured":"Rolfes L, et al. Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Commun. 2021;3(3):fcab157.","journal-title":"Brain Commun"},{"issue":"7916","key":"619_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-022-04844-5","volume":"606","author":"L Campisi","year":"2022","unstructured":"Campisi L, et al. Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4. Nature. 2022;606(7916):945\u201352.","journal-title":"Nature"},{"key":"619_CR20","first-page":"e200042","volume-title":"Senescent-like blood lymphocytes and disease progression in amyotrophic lateral sclerosis","author":"O Yildiz","year":"2022","unstructured":"Yildiz O, Schroth J, Tree T, Turner MR, Shaw PJ, Henson SM, Malaspina A. Senescent-like blood lymphocytes and disease progression in amyotrophic lateral sclerosis. Volume 10. Neurology: Neuroimmunology & Neuroinflammation; 2022. p. e200042. 1."},{"issue":"6","key":"619_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492\u2013506.","journal-title":"Cell Res"},{"issue":"7770","key":"619_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-019-1443-5","volume":"572","author":"E Blacher","year":"2019","unstructured":"Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474\u201380.","journal-title":"Nature"},{"issue":"6415","key":"619_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, et al. Mutations in Cu\/Zn Superoxide-Dismutase Gene are Associated with familial amyotrophic-lateral-sclerosis. Nature. 1993;362(6415):59\u201362.","journal-title":"Nature"},{"issue":"5166","key":"619_CR24","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772\u20135.","journal-title":"Science"},{"issue":"5870","key":"619_CR25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","volume":"319","author":"J Sreedharan","year":"2008","unstructured":"Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668\u201372.","journal-title":"Science"},{"issue":"5918","key":"619_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"C Vance","year":"2009","unstructured":"Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208\u201311.","journal-title":"Science"},{"issue":"1","key":"619_CR27","doi-asserted-by":"publisher","first-page":"dmm037424","DOI":"10.1242\/dmm.037424","volume":"12","author":"F De Giorgio","year":"2019","unstructured":"De Giorgio F, et al. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech. 2019;12(1):dmm037424. https:\/\/doi.org\/10.1242\/dmm.037424.","journal-title":"Dis Model Mech"},{"issue":"4","key":"619_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41583-022-00564-x","volume":"23","author":"TW Todd","year":"2022","unstructured":"Todd TW, Petrucelli L. Modelling amyotrophic lateral sclerosis in rodents. Nat Rev Neurosci. 2022;23(4):231\u201351.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"619_CR29","doi-asserted-by":"publisher","first-page":"e0255710","DOI":"10.1371\/journal.pone.0255710","volume":"17","author":"C Yang","year":"2022","unstructured":"Yang C, et al. Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. PLoS ONE. 2022;17(2):e0255710.","journal-title":"PLoS ONE"},{"issue":"11","key":"619_CR30","doi-asserted-by":"publisher","first-page":"e98684","DOI":"10.15252\/embj.201798684","volume":"37","author":"P Fratta","year":"2018","unstructured":"Fratta P, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37(11):e98684. https:\/\/doi.org\/10.15252\/embj.201798684.","journal-title":"EMBO J"},{"issue":"4","key":"619_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41593-018-0113-5","volume":"21","author":"MA White","year":"2018","unstructured":"White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552\u201363.","journal-title":"Nat Neurosci"},{"issue":"1","key":"619_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41398-020-01078-9","volume":"10","author":"E Kim","year":"2020","unstructured":"Kim E, et al. Coexistence of perseveration and apathy in the TDP-43(Q331K) knock-in mouse model of ALS-FTD. Transl Psychiatry. 2020;10(1):377.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"619_CR33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.celrep.2018.12.045","volume":"26","author":"SY Ebstein","year":"2019","unstructured":"Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage Dose-Dependent Motor Neuron Degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 2019;26(2):364\u201373. e4.","journal-title":"Cell Rep"},{"issue":"1","key":"619_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-020-0881-5","volume":"8","author":"SL Huang","year":"2020","unstructured":"Huang SL, et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;8(1):3.","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"619_CR35","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/brain\/awx248","volume":"140","author":"A Devoy","year":"2017","unstructured":"Devoy A, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in \u2018FUSDelta14\u2019 knockin mice. Brain. 2017;140(11):2797\u2013805.","journal-title":"Brain"},{"issue":"12","key":"619_CR36","doi-asserted-by":"publisher","first-page":"103463","DOI":"10.1016\/j.isci.2021.103463","volume":"24","author":"A Devoy","year":"2021","unstructured":"Devoy A, et al. Generation and analysis of innovative genomically humanized knockin SOD1, TARDBP (TDP-43), and FUS mouse models. iScience. 2021;24(12):103463.","journal-title":"iScience"},{"issue":"10","key":"619_CR37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.15252\/embj.201592559","volume":"35","author":"J Scekic-Zahirovic","year":"2016","unstructured":"Scekic-Zahirovic J, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077\u201397.","journal-title":"EMBO J"},{"issue":"1","key":"619_CR38","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41467-019-09716-7","volume":"10","author":"F Zhu","year":"2019","unstructured":"Zhu F, et al. Humanising the mouse genome piece by piece. Nat Commun. 2019;10(1):1845.","journal-title":"Nat Commun"},{"issue":"7\u20138","key":"619_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00335-019-09807-2","volume":"30","author":"RR Nair","year":"2019","unstructured":"Nair RR, et al. Uses for humanised mouse models in precision medicine for neurodegenerative disease. Mamm Genome. 2019;30(7\u20138):173\u201391.","journal-title":"Mamm Genome"},{"issue":"5","key":"619_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1242\/dmm.007237","volume":"4","author":"A Acevedo-Arozena","year":"2011","unstructured":"Acevedo-Arozena A, et al. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech. 2011;4(5):686\u2013700.","journal-title":"Dis Model Mech"},{"issue":"1","key":"619_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/brain\/awac306","volume":"146","author":"D Ito","year":"2023","unstructured":"Ito D, et al. Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain. 2023;146(1):13\u20139.","journal-title":"Brain"},{"issue":"4","key":"619_CR42","doi-asserted-by":"publisher","first-page":"fcab242","DOI":"10.1093\/braincomms\/fcab242","volume":"3","author":"C Wong","year":"2021","unstructured":"Wong C, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242.","journal-title":"Brain Commun"},{"issue":"12","key":"619_CR43","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41588-021-00981-1","volume":"53","author":"S Sahdeo","year":"2021","unstructured":"Sahdeo S, Goldstein DB. Translating amyotrophic lateral sclerosis genes into drug development leads. Nat Genet. 2021;53(12):1624\u20136.","journal-title":"Nat Genet"},{"issue":"6248","key":"619_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.aab0983","volume":"349","author":"JP Ling","year":"2015","unstructured":"Ling JP, et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650\u20135.","journal-title":"Science"},{"issue":"4","key":"619_CR45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41593-022-01040-6","volume":"25","author":"C Eitan","year":"2022","unstructured":"Eitan C, et al. Whole-genome sequencing reveals that variants in the Interleukin 18 receptor accessory protein 3\u2019UTR protect against ALS. Nat Neurosci. 2022;25(4):433\u201345.","journal-title":"Nat Neurosci"},{"issue":"Pt 9","key":"619_CR46","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/brain\/awr159","volume":"134","author":"V Swarup","year":"2011","unstructured":"Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis\/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610\u201326.","journal-title":"Brain"},{"issue":"3","key":"619_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, et al. Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2014;127(3):441\u201350.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"619_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/neup.12053","volume":"34","author":"Y Toyoshima","year":"2014","unstructured":"Toyoshima Y, Takahashi H. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis. Neuropathology. 2014;34(1):77\u201382.","journal-title":"Neuropathology"},{"issue":"6","key":"619_CR49","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327.","journal-title":"Brain"},{"issue":"1","key":"619_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/toxsci\/kfy267","volume":"167","author":"PEA Ash","year":"2019","unstructured":"Ash PEA, et al. Heavy metal neurotoxicants induce ALS-Linked TDP-43 Pathology. Toxicol Sci. 2019;167(1):105\u201315.","journal-title":"Toxicol Sci"},{"issue":"2","key":"619_CR51","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s13311-021-01015-8","volume":"18","author":"SS Thammisetty","year":"2021","unstructured":"Thammisetty SS, et al. Targeting TDP-43 Pathology alleviates cognitive and motor deficits caused by chronic cerebral hypoperfusion. Neurotherapeutics. 2021;18(2):1095\u2013112.","journal-title":"Neurotherapeutics"},{"issue":"6529","key":"619_CR52","doi-asserted-by":"publisher","first-page":"eabb4309","DOI":"10.1126\/science.abb4309","volume":"371","author":"H Yu","year":"2021","unstructured":"Yu H, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371(6529):eabb4309. https:\/\/doi.org\/10.1126\/science.abb4309.","journal-title":"Science"},{"issue":"8","key":"619_CR53","doi-asserted-by":"publisher","first-page":"E736","DOI":"10.1073\/pnas.1222809110","volume":"110","author":"ES Arnold","year":"2013","unstructured":"Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110(8):E736\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"619_CR54","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1038\/s41467-018-06548-9","volume":"9","author":"S Porta","year":"2018","unstructured":"Porta S, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9(1):4220.","journal-title":"Nat Commun"},{"key":"619_CR55","doi-asserted-by":"publisher","first-page":"106050","DOI":"10.1016\/j.nbd.2023.106050","volume":"179","author":"T Afroz","year":"2023","unstructured":"Afroz T, et al. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS\/FTD. Neurobiol Dis. 2023;179:106050.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"619_CR56","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1172\/JCI44867","volume":"121","author":"LM Igaz","year":"2011","unstructured":"Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726\u201338.","journal-title":"J Clin Invest"},{"key":"619_CR57","doi-asserted-by":"publisher","first-page":"103840","DOI":"10.1016\/j.mcn.2023.103840","volume":"125","author":"AN Bak","year":"2023","unstructured":"Bak AN, Djukic S, Kadlecova M, Braunstein TH, Jensen DB, Meehan CF. Cytoplasmic TDP-43 accumulation drives changes in C-bouton number and size in a mouse model of sporadic Amyotrophic Lateral Sclerosis. Mol Cell Neurosci. 2023;125:103840. https:\/\/doi.org\/10.1016\/j.mcn.2023.103840.","journal-title":"Mol Cell Neurosci."},{"key":"619_CR58","doi-asserted-by":"crossref","unstructured":"Sanchez-Rivera FJ et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci USA. 2021;118(23).","DOI":"10.1073\/pnas.2019740118"},{"issue":"7","key":"619_CR59","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","volume":"127","author":"CP Martins","year":"2006","unstructured":"Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323\u201334.","journal-title":"Cell"},{"issue":"7128","key":"619_CR60","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656\u201360.","journal-title":"Nature"},{"issue":"7323","key":"619_CR61","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nature09526","volume":"468","author":"MR Junttila","year":"2010","unstructured":"Junttila MR, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010;468(7323):567\u201371.","journal-title":"Nature"},{"issue":"7775","key":"619_CR62","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41586-019-1577-5","volume":"573","author":"JPt Morris","year":"2019","unstructured":"Morris JPt, et al. Alpha-ketoglutarate links p53 to cell fate during tumour suppression. Nature. 2019;573(7775):595\u20139.","journal-title":"Nature"},{"issue":"7863","key":"619_CR63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-021-03525-z","volume":"594","author":"DJ Flanagan","year":"2021","unstructured":"Flanagan DJ, et al. NOTUM from apc-mutant cells biases clonal competition to initiate cancer. Nature. 2021;594(7863):430\u20135.","journal-title":"Nature"},{"issue":"7917","key":"619_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-022-04839-2","volume":"607","author":"AM Jaeger","year":"2022","unstructured":"Jaeger AM, et al. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022;607(7917):149\u201355.","journal-title":"Nature"},{"issue":"1","key":"619_CR65","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1212\/NXG.0000000000000552","volume":"7","author":"S Hisahara","year":"2021","unstructured":"Hisahara S, et al. Possible somatic mosaicism of novel FUS variant in familial amyotrophic lateral sclerosis. Neurol Genet. 2021;7(1):e552.","journal-title":"Neurol Genet"},{"key":"619_CR66","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1073\/pnas.0909343106","volume":"107","author":"SA Frank","year":"2010","unstructured":"Frank SA. Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010;107:1725\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"619_CR67","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S1474-4422(14)70219-4","volume":"13","author":"A Al-Chalabi","year":"2014","unstructured":"Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108\u201313.","journal-title":"Lancet Neurol"},{"issue":"9\u201310","key":"619_CR68","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1242\/dmm.001644","volume":"2","author":"EM Fisher","year":"2009","unstructured":"Fisher EM, et al. New approaches for modelling sporadic genetic disease in the mouse. Dis Model Mech. 2009;2(9\u201310):446\u201353.","journal-title":"Dis Model Mech"},{"issue":"12","key":"619_CR69","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","volume":"29","author":"DA Amado","year":"2021","unstructured":"Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29(12):3345\u201358.","journal-title":"Mol Ther"},{"issue":"1","key":"619_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12955-022-01919-9","volume":"20","author":"SL Hartmaier","year":"2022","unstructured":"Hartmaier SL, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"619_CR71","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","volume":"24","author":"I Magen","year":"2021","unstructured":"Magen I, et al. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci. 2021;24(11):1534\u201341.","journal-title":"Nat Neurosci"},{"issue":"2","key":"619_CR72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ana.26285","volume":"91","author":"S Paganoni","year":"2022","unstructured":"Paganoni S, et al. Adaptive platform trials to transform amyotrophic lateral sclerosis Therapy Development. Ann Neurol. 2022;91(2):165\u201375.","journal-title":"Ann Neurol"},{"key":"619_CR73","doi-asserted-by":"publisher","unstructured":"Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv [Preprint]. 2023;2023:01.23.525202. https:\/\/doi.org\/10.1101\/2023.01.23.525202.\u00a0","DOI":"10.1101\/2023.01.23.525202"},{"issue":"2","key":"619_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","volume":"17","author":"MC Kiernan","year":"2021","unstructured":"Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"619_CR75","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.25661","volume":"87","author":"AC Ludolph","year":"2020","unstructured":"Ludolph AC, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206\u201316.","journal-title":"Ann Neurol"},{"issue":"1","key":"619_CR76","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1038\/s41598-019-40632-4","volume":"9","author":"E Leoni","year":"2019","unstructured":"Leoni E, et al. Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):4478.","journal-title":"Sci Rep"},{"issue":"5\u20136","key":"619_CR77","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio A, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5\u20136):310\u201323.","journal-title":"Amyotroph Lateral Scler"},{"issue":"1","key":"619_CR78","doi-asserted-by":"publisher","first-page":"fcac029","DOI":"10.1093\/braincomms\/fcac029","volume":"4","author":"AG Thompson","year":"2022","unstructured":"Thompson AG, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4(1):fcac029.","journal-title":"Brain Commun"},{"issue":"2","key":"619_CR79","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/17482968.2010.550626","volume":"12","author":"TD Heiman-Patterson","year":"2011","unstructured":"Heiman-Patterson TD, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler. 2011;12(2):79\u201386.","journal-title":"Amyotroph Lateral Scler"},{"issue":"1","key":"619_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41232-023-00270-w","volume":"43","author":"C Margotta","year":"2023","unstructured":"Margotta C, et al. Immune-mediated myogenesis and acetylcholine receptor clustering promote a slow disease progression in ALS mouse models. Inflamm Regen. 2023;43(1):19.","journal-title":"Inflamm Regen"},{"key":"619_CR81","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fnins.2019.01276","volume":"13","author":"GN Valbuena","year":"2019","unstructured":"Valbuena GN, et al. Spinal cord metabolic signatures in models of fast- and slow-progressing SOD1(G93A) amyotrophic lateral sclerosis. Front Neurosci. 2019;13:1276.","journal-title":"Front Neurosci"},{"issue":"4","key":"619_CR82","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nm1021","volume":"10","author":"D Kieran","year":"2004","unstructured":"Kieran D, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402\u20135.","journal-title":"Nat Med"},{"issue":"7","key":"619_CR83","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","volume":"90","author":"M Benatar","year":"2018","unstructured":"Benatar M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565\u201374.","journal-title":"Neurology"},{"key":"619_CR84","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1741-7007-10-96","volume":"10","author":"BH Chaiyachati","year":"2012","unstructured":"Chaiyachati BH, et al. LoxP-FRT trap (LOFT): a simple and flexible system for conventional and reversible gene targeting. BMC Biol. 2012;10:96.","journal-title":"BMC Biol"},{"key":"619_CR85","doi-asserted-by":"publisher","first-page":"8783","DOI":"10.1038\/ncomms9783","volume":"6","author":"C Robles-Oteiza","year":"2015","unstructured":"Robles-Oteiza C, et al. Recombinase-based conditional and reversible gene regulation via XTR alleles. Nat Commun. 2015;6:8783.","journal-title":"Nat Commun"},{"key":"619_CR86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fnmol.2013.00018","volume":"6","author":"N Smedemark-Margulies","year":"2013","unstructured":"Smedemark-Margulies N, Trapani JG. Tools, methods, and applications for optophysiology in neuroscience. Front Mol Neurosci. 2013;6:18.","journal-title":"Front Mol Neurosci"},{"key":"619_CR87","doi-asserted-by":"publisher","first-page":"106022","DOI":"10.1016\/j.nbd.2023.106022","volume":"178","author":"M Gautam","year":"2023","unstructured":"Gautam M, et al. SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function. Neurobiol Dis. 2023;178:106022.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"619_CR88","doi-asserted-by":"publisher","first-page":"e20200487","DOI":"10.1084\/jem.20200487","volume":"218","author":"DN Kasal","year":"2021","unstructured":"Kasal DN, Bendelac A. Multi-transcription factor reporter mice delineate early precursors to the ILC and LTi lineages. J Exp Med. 2021;218(2):e20200487. https:\/\/doi.org\/10.1084\/jem.20200487.","journal-title":"J Exp Med"},{"issue":"19","key":"619_CR89","doi-asserted-by":"publisher","first-page":"e107260","DOI":"10.15252\/embj.2020107260","volume":"40","author":"S Blumenstock","year":"2021","unstructured":"Blumenstock S, et al. Fluc-EGFP reporter mice reveal differential alterations of neuronal proteostasis in aging and disease. EMBO J. 2021;40(19):e107260.","journal-title":"EMBO J"},{"key":"619_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac415","author":"JJ Wlaschin","year":"2022","unstructured":"Wlaschin JJ, et al. Promoting regeneration while blocking cell death preserves motor neuron function in a model of ALS. Brain. 2022. https:\/\/doi.org\/10.1093\/brain\/awac415.","journal-title":"Brain"},{"issue":"3","key":"619_CR91","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz M, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29(3):632\u201345.","journal-title":"Nat Med"},{"key":"619_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2023.02.010","volume":"126","author":"FJ Arnold","year":"2023","unstructured":"Arnold FJ, et al. Chronic BMAA exposure combined with TDP-43 mutation elicits motor neuron dysfunction phenotypes in mice. Neurobiol Aging. 2023;126:44\u201357.","journal-title":"Neurobiol Aging"},{"issue":"48","key":"619_CR93","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1073\/pnas.1318268110","volume":"110","author":"JC Watts","year":"2013","unstructured":"Watts JC, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013;110(48):19555\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"619_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40478-018-0529-x","volume":"6","author":"A Ruiz-Riquelme","year":"2018","unstructured":"Ruiz-Riquelme A, et al. Prion-like propagation of beta-amyloid aggregates in the absence of APP overexpression. Acta Neuropathol Commun. 2018;6(1):26.","journal-title":"Acta Neuropathol Commun"},{"issue":"7736","key":"619_CR95","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-018-0790-y","volume":"564","author":"SA Purro","year":"2018","unstructured":"Purro SA, et al. Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone. Nature. 2018;564(7736):415\u20139.","journal-title":"Nature"},{"key":"619_CR96","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fnmol.2019.00262","volume":"12","author":"L McAlary","year":"2019","unstructured":"McAlary L, et al. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262.","journal-title":"Front Mol Neurosci"},{"key":"619_CR97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","volume":"40","author":"M Goedert","year":"2017","unstructured":"Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017;40:189\u2013210.","journal-title":"Annu Rev Neurosci"},{"issue":"7628","key":"619_CR98","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature20415","volume":"539","author":"J Collinge","year":"2016","unstructured":"Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539(7628):217\u201326.","journal-title":"Nature"},{"key":"619_CR99","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","volume":"42","author":"CF Bennett","year":"2019","unstructured":"Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative Diseases. Annu Rev Neurosci. 2019;42:385\u2013406.","journal-title":"Annu Rev Neurosci"},{"issue":"8","key":"619_CR100","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558\u201367.","journal-title":"J Clin Invest"},{"key":"619_CR101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.pathol.3.121806.154244","volume":"6","author":"DJ Cheon","year":"2011","unstructured":"Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95\u2013119.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"619_CR102","doi-asserted-by":"publisher","first-page":"188554","DOI":"10.1016\/j.bbcan.2021.188554","volume":"1876","author":"K Mallya","year":"2021","unstructured":"Mallya K, et al. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188554.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"619_CR103","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/cancers14010071","volume":"14","author":"Y Saiki","year":"2021","unstructured":"Saiki Y, et al. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers (Basel). 2021;14(1):71. https:\/\/doi.org\/10.3390\/cancers14010071.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"619_CR104","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.gde.2012.01.004","volume":"22","author":"MH van Miltenburg","year":"2012","unstructured":"van Miltenburg MH, Jonkers J. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev. 2012;22(1):21\u20137.","journal-title":"Curr Opin Genet Dev"},{"issue":"7","key":"619_CR105","doi-asserted-by":"publisher","first-page":"e064173","DOI":"10.1136\/bmjopen-2022-064173","volume":"12","author":"C Wong","year":"2022","unstructured":"Wong C, et al. Motor Neuron Disease systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12(7):e064173.","journal-title":"BMJ Open"},{"issue":"7\u20138","key":"619_CR106","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/21678421.2020.1788092","volume":"21","author":"RPA van Eijk","year":"2020","unstructured":"van Eijk RPA, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7\u20138):496\u2013501.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-023-00619-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T19:07:24Z","timestamp":1683227244000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-023-00619-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1186\/s13024-023-00619-2","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}